September 2, 2016
Genetic Signatures Limited Completes $14m Capital Raising
Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that it has successfully completed an institutional placement to raise $14 million through the issue of 29.8 million new shares (Offer).
The proceeds from the Offer will be used for commercial expansion in Australia, the European Union and USA, obtaining further regulatory approvals for Genetic Signatures’ products, continued product development and working capital purposes.
August 30, 2016
Preliminary Final Report – GSS Appendix 4E 30 June 2016
July 22, 2016
GSS Non-Deal Roadshow Presentation – July 2016
July 21, 2016
Quarterly Cash Flow & Activities Report – GSS Appendix 4C 30 June 2016
June 17, 2016
Genetic Signatures Launches Analyte Specific Reagents in the US
- Further step towards full product suite commercialisation in the US
- Allows uptake of Genetic Signatures 3base™ technology in up to 11,000 CLIA certified laboratories in the US
- To be officially launched during the American Society of Microbiology conference on June 17, 2016
Sydney, Australia, 17 June, 2016: Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) will today launch a range of Analyte Specific Reagents (ASRs) in the United States. These ASR products utilise the company’s proprietary 3base™ technology and cover a range of pathogen targets. US Laboratories regulated by the Clinical Laboratory Improvement Act (CLIA) may purchase and use ASRs as building blocks to develop and validate proprietary tests for the diagnosis of infectious diseases. These laboratory-developed tests are commonly used in the US market and are offered in up to 11,000 CLIA certified laboratories1.
The ASR products will be officially launched at the American Society of Microbiology conference, Boston, June 17-20, 2016. Genetic Signatures will be exhibiting and showcasing their full product range to more than 10,000 attendees.
“We know that the market in the US seeks technologically superior products that may be used in laboratory-developed tests.” said Mr. Mike Aicher, President of Genetic Signatures US. “This is the next logical step for Genetic Signatures after FDA listing of our Clinical Concentrator Kit, which we completed in August of 2015.”
“This progressive step in our US market entry strategy brings our proprietary 3Base™ technology to the majority of hospital and commercial laboratories in the US,” said Genetic Signatures’ Chief Executive Officer, John Melki PhD. “We believe that our technologically superior ASRs will be well received by the American market.”
About Analyte Specific Reagents: The US Food and Drug Administration (FDA) defines Analyte Specific Reagents as “antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents, which through specific binding or chemical reactions with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens.” 21 CFR 864.4020
1http://www.acla.com/wp-content/uploads/sites/4/2014/09/Alan-Mertz-Written-Statement-for-21st-Century-Cures-Hearing-2014-09-09.pdf
April 28, 2016
Quarterly Cash Flow & Activities Report – GSS Amended Appendix 4C 31 March 2016
February 26, 2016
Half-Yearly Cash Flow and Activities Report – GSS Appendix 4D 31 December 2015
January 29, 2016
Quarterly Cash Flow & Activities Report – GSS Amended Appendix 4C 31 December 2015
November 6, 2015
University of California Los Angeles to Collaborate with Genetic Signatures on Transformative Molecular Platform Technology
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced a collaboration with Dr. Scott Binder MD and his Microbiology team at the University of California, Los Angeles (UCLA) to analyze molecular testing methods for bacteria, viruses and parasites as compared to traditional testing in an effort to reduce the spread of infection in the US healthcare system.
